HC Wainwright Weighs in on GH Research FY2024 Earnings

GH Research PLC (NASDAQ:GHRS) – Equities research analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for GH Research in a report released on Monday, January 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.80) per share for the year, down from their prior forecast of ($0.76). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for GH Research’s Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.94) EPS and FY2028 earnings at ($0.49) EPS.

Separately, Canaccord Genuity Group reduced their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th.

GH Research Trading Up 7.8 %

Shares of NASDAQ GHRS opened at $9.50 on Wednesday. GH Research has a 12 month low of $6.00 and a 12 month high of $14.99. The stock has a 50 day moving average of $8.41 and a 200-day moving average of $8.92. The company has a market capitalization of $494.29 million, a P/E ratio of -12.03 and a beta of 0.84.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its stake in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the quarter. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).